11 Einträge gefunden

1. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

   1. Avet-Loiseau, Hervé
   2. San-Miguel, Jesus
   3. Casneuf, Tineke
   4. Iida, Shinsuke
   5. Lonial, Sagar
   6. Usmani, Saad Z
   7. Spencer, Andrew

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
2. Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma

   1. Siegel, David
   2. Weisel, Katja
   3. Zahlten-Kumeli, Anita
   4. Medhekar, Rohan
   5. Ding, Bifeng
   6. Leleu, Xavier

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Selective elimination of immunosuppressive T cells in patients with multiple myeloma

   1. Awwad, Mohamed H S
   2. Mahmoud, Abdelrahman
   3. Bruns, Heiko
   4. Echchannaoui, Hakim
   5. Kriegsmann, Katharina
   6. Lutz, Raphael
   7. Raab, Marc S

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
4. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study

   1. Lonial, Sagar
   2. Lee, Hans C
   3. Badros, Ashraf
   4. Trudel, Suzanne
   5. Nooka, Ajay K
   6. Chari, Ajai
   7. Abdallah, Al-Ola

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
5. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

   1. Dimopoulos, Meletios
   2. Weisel, Katja
   3. Moreau, Philippe
   4. Anderson, Larry D
   5. White, Darrell
   6. San-Miguel, Jesus
   7. Sonneveld, Pieter

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
6. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

   1. Nooka, Ajay K
   2. Weisel, Katja
   3. van de Donk, Niels Wcj
   4. Routledge, David
   5. Otero, Paula Rodriguez
   6. Song, Kevin
   7. Quach, Hang

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
7. Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options

   1. Ramasamy, Karthik
   2. Gay, Francesca
   3. Weisel, Katja
   4. Zweegman, Sonja
   5. Mateos, Maria Victoria
   6. Richardson, Paul

   2021 - Forschungsinformationssystem des UKE
8. Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR

   1. Weisel, Katja
   2. Mateos, Maria-Victoria
   3. Gay, Francesca
   4. Delforge, Michel
   5. Cook, Gordon
   6. Szabo, Zsolt
   7. Desgraz, Renaud

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
9. Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

   1. Chari, Ajai
   2. Munder, Markus
   3. Weisel, Katja
   4. Jenner, Matthew
   5. Bygrave, Ceri
   6. Petrucci, Maria Teresa
   7. Boccadoro, Mario

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
10. Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma

    1. Radocha, Jakub
    2. van de Donk, Niels W C J
    3. Weisel, Katja

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
11. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma

    1. Rodriguez-Otero, Paula
    2. Ayers, Dieter
    3. Cope, Shannon
    4. Davies, Faith E
    5. Delforge, Michel
    6. Mojebi, Ali
    7. Jansen, Jeroen P

    2021 - Forschungsinformationssystem des UKE - frei zugänglich